<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Contagion Live articles</title><description>Contagion Live articles</description><link>https://www.contagionlive.com/news</link><category>Contagion Live articles</category><copyright>© 2026 MJH Life Sciences™ and Contagion Live. All rights reserved.</copyright><lastBuildDate>Mon, 26 Oct 2026 22:40:37 +0000</lastBuildDate><ttl>5</ttl><atom:link href="https://www.contagionlive.com/rss.xml" rel="self" type="application/rss+xml"/><language>en-us</language><image><title>Contagion Live articles</title><width>144</width><height>47</height><link>https://www.contagionlive.com/news</link><url>https://www.contagionlive.com/logo.webp</url></image><item><title>&lt;![CDATA[Novel RSV Therapy: Addressing a Clinical Need ]]&gt;</title><link>https://www.contagionlive.com/view/novel-rsv-therapy-addressing-a-clinical-need</link><guid isPermaLink="true">https://www.contagionlive.com/view/novel-rsv-therapy-addressing-a-clinical-need</guid><description>&lt;![CDATA[Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.]]&gt;</description><pubDate>Mon, 26 Oct 2026 16:32:04 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial]]&gt;</title><link>https://www.contagionlive.com/view/early-dual-therapy-shortens-staphylococcus-aureus-bacteremia-in-sabedtio-trial</link><guid isPermaLink="true">https://www.contagionlive.com/view/early-dual-therapy-shortens-staphylococcus-aureus-bacteremia-in-sabedtio-trial</guid><description>&lt;![CDATA[Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.]]&gt;</description><pubDate>Mon, 26 Oct 2026 10:48:01 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants]]&gt;</title><link>https://www.contagionlive.com/view/pfizer-25-valent-pneumococcal-vaccine-boosts-serotype-3-response-in-infants</link><guid isPermaLink="true">https://www.contagionlive.com/view/pfizer-25-valent-pneumococcal-vaccine-boosts-serotype-3-response-in-infants</guid><description>&lt;![CDATA[Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.]]&gt;</description><pubDate>Sun, 25 Oct 2026 12:50:08 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record]]&gt;</title><link>https://www.contagionlive.com/view/ebola-update-drc-outbreak-reaches-9735-cases-second-largest-on-record</link><guid isPermaLink="true">https://www.contagionlive.com/view/ebola-update-drc-outbreak-reaches-9735-cases-second-largest-on-record</guid><description>&lt;![CDATA[CDC says the Bundibugyo virus outbreak in the DRC is the second-largest Ebola outbreak on record, with 9735 confirmed cases and 4690 deaths.]]&gt;</description><pubDate>Sun, 25 Oct 2026 12:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events]]&gt;</title><link>https://www.contagionlive.com/view/early-antibiotic-stop-neutropenic-fever-not-raise-severe-events</link><guid isPermaLink="true">https://www.contagionlive.com/view/early-antibiotic-stop-neutropenic-fever-not-raise-severe-events</guid><description>&lt;![CDATA[Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.]]&gt;</description><pubDate>Sat, 24 Oct 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapy]]&gt;</title><link>https://www.contagionlive.com/view/asuptegravir-lowers-hiv-1-rna-2-36-logs-early-monotherapy</link><guid isPermaLink="true">https://www.contagionlive.com/view/asuptegravir-lowers-hiv-1-rna-2-36-logs-early-monotherapy</guid><description>&lt;![CDATA[Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.]]&gt;</description><pubDate>Sat, 24 Oct 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Fecal Microbiota Spores Cut Early Hospitalizations in Recurrent C diff]]&gt;</title><link>https://www.contagionlive.com/view/fecal-microbiota-spores-cut-early-hospitalizations-recurrent-c-diff</link><guid isPermaLink="true">https://www.contagionlive.com/view/fecal-microbiota-spores-cut-early-hospitalizations-recurrent-c-diff</guid><description>&lt;![CDATA[In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.]]&gt;</description><pubDate>Sat, 24 Oct 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[CDC Tracking 5 Active Food-Borne Outbreaks Tied to Oysters, Cheese, Sprouts]]&gt;</title><link>https://www.contagionlive.com/view/cdc-5-active-food-borne-outbreaks-oysters-cheese-sprouts</link><guid isPermaLink="true">https://www.contagionlive.com/view/cdc-5-active-food-borne-outbreaks-oysters-cheese-sprouts</guid><description>&lt;![CDATA[CDC lists 5 active multistate outbreaks tied to oysters, raw milk cheese, sprouts, and pet turtles, with recalls in effect for 4 of them.]]&gt;</description><pubDate>Sat, 24 Oct 2026 12:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases]]&gt;</title><link>https://www.contagionlive.com/view/ensitrelvir-pep-eases-symptom-severity-in-covid-19-breakthrough-cases</link><guid isPermaLink="true">https://www.contagionlive.com/view/ensitrelvir-pep-eases-symptom-severity-in-covid-19-breakthrough-cases</guid><description>&lt;![CDATA[Exploratory SCORPIO-PEP data presented at IDWeek 2026 show household contacts with breakthrough COVID-19 on ensitrelvir had lower peak viral RNA and fewer severe symptoms than placebo recipients.]]&gt;</description><pubDate>Sat, 24 Oct 2026 10:50:03 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Oral Olorofim Noninferior to AmBisome in Phase 3 OASIS Trial]]&gt;</title><link>https://www.contagionlive.com/view/oral-olorofim-noninferior-ambisome-phase-3-oasis-trial</link><guid isPermaLink="true">https://www.contagionlive.com/view/oral-olorofim-noninferior-ambisome-phase-3-oasis-trial</guid><description>&lt;![CDATA[Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.]]&gt;</description><pubDate>Fri, 23 Oct 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Aztreonam-Avibactam Holds Activity as MBL-Producing CRE Rise in US]]&gt;</title><link>https://www.contagionlive.com/view/aztreonam-avibactam-holds-activity-mbl-producing-cre-rise</link><guid isPermaLink="true">https://www.contagionlive.com/view/aztreonam-avibactam-holds-activity-mbl-producing-cre-rise</guid><description>&lt;![CDATA[MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.]]&gt;</description><pubDate>Fri, 23 Oct 2026 17:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Bictegravir/Lenacapavir Well Tolerated in HIV With Comorbidities]]&gt;</title><link>https://www.contagionlive.com/view/bictegravir-lenacapavir-well-tolerated-hiv-comorbidities</link><guid isPermaLink="true">https://www.contagionlive.com/view/bictegravir-lenacapavir-well-tolerated-hiv-comorbidities</guid><description>&lt;![CDATA[Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.]]&gt;</description><pubDate>Fri, 23 Oct 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Measles Update: October 23, 2026]]&gt;</title><link>https://www.contagionlive.com/view/measles-update-october-23-2026</link><guid isPermaLink="true">https://www.contagionlive.com/view/measles-update-october-23-2026</guid><description>&lt;![CDATA[The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.]]&gt;</description><pubDate>Fri, 23 Oct 2026 14:54:59 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Household Contacts Drive Most Hepatitis B Exposures in Young Children]]&gt;</title><link>https://www.contagionlive.com/view/household-contacts-drive-most-hepatitis-b-exposures-in-young-children</link><guid isPermaLink="true">https://www.contagionlive.com/view/household-contacts-drive-most-hepatitis-b-exposures-in-young-children</guid><description>&lt;![CDATA[Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.]]&gt;</description><pubDate>Fri, 23 Oct 2026 14:24:08 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Isavuconazole Has Lowest Hepatotoxicity Signal Among Azoles in FAERS]]&gt;</title><link>https://www.contagionlive.com/view/isavuconazole-lowest-hepatotoxicity-signal-among-azoles-faers</link><guid isPermaLink="true">https://www.contagionlive.com/view/isavuconazole-lowest-hepatotoxicity-signal-among-azoles-faers</guid><description>&lt;![CDATA[Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.]]&gt;</description><pubDate>Fri, 23 Oct 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Zoliflodacin Holds Gonorrhea Cure Rates in Chlamydia Coinfected Patients]]&gt;</title><link>https://www.contagionlive.com/view/zoliflodacin-holds-gonorrhea-cure-rates-in-chlamydia-coinfected-patients</link><guid isPermaLink="true">https://www.contagionlive.com/view/zoliflodacin-holds-gonorrhea-cure-rates-in-chlamydia-coinfected-patients</guid><description>&lt;![CDATA[Data being presented at IDWeek 2026 show zoliflodacin maintains high gonorrhea cure rates in patients co-infected with chlamydia. David Altarac, MD, discusses the therapy and the study being presented at the conference.]]&gt;</description><pubDate>Fri, 23 Oct 2026 09:36:39 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE]]&gt;</title><link>https://www.contagionlive.com/view/inhaled-amikacin-shows-low-resistance-rates-in-mac-lung-disease-in-encore</link><guid isPermaLink="true">https://www.contagionlive.com/view/inhaled-amikacin-shows-low-resistance-rates-in-mac-lung-disease-in-encore</guid><description>&lt;![CDATA[In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.]]&gt;</description><pubDate>Thu, 22 Oct 2026 20:18:01 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1]]&gt;</title><link>https://www.contagionlive.com/view/pritelivir-cuts-hospital-days-refractory-hsv-phase-3-prioh-1</link><guid isPermaLink="true">https://www.contagionlive.com/view/pritelivir-cuts-hospital-days-refractory-hsv-phase-3-prioh-1</guid><description>&lt;![CDATA[Oral pritelivir improved lesion healing and cut hospitalizations from 76% to 29.4% vs investigator&apos;s choice therapy in immunocompromised patients with refractory HSV.]]&gt;</description><pubDate>Thu, 22 Oct 2026 19:30:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria]]&gt;</title><link>https://www.contagionlive.com/view/cefiderocol-xeruborbactam-active-against-carbapenem-resistant-bacteria</link><guid isPermaLink="true">https://www.contagionlive.com/view/cefiderocol-xeruborbactam-active-against-carbapenem-resistant-bacteria</guid><description>&lt;![CDATA[Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.]]&gt;</description><pubDate>Thu, 22 Oct 2026 17:30:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Zelicapavir Shortens RSV Symptoms Despite Missing Primary End Point]]&gt;</title><link>https://www.contagionlive.com/view/zelicapavir-shortens-rsv-symptoms-misses-primary-end-point</link><guid isPermaLink="true">https://www.contagionlive.com/view/zelicapavir-shortens-rsv-symptoms-misses-primary-end-point</guid><description>&lt;![CDATA[Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.]]&gt;</description><pubDate>Thu, 22 Oct 2026 15:30:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[FDA Approves Bepirovirsen, First Antisense Therapy for Chronic Hepatitis B]]&gt;</title><link>https://www.contagionlive.com/view/fda-approves-hibsago-first-antisense-therapy-chronic-hepatitis-b</link><guid isPermaLink="true">https://www.contagionlive.com/view/fda-approves-hibsago-first-antisense-therapy-chronic-hepatitis-b</guid><description>&lt;![CDATA[The FDA approved bepirovirsen (Hibsago; GSK) with nucleos(t)ide analogue therapy for chronic hepatitis B, based on B-Well 1 and 2 functional cure rates of 19% vs 0% with placebo.]]&gt;</description><pubDate>Wed, 21 Oct 2026 13:40:41 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[LMN-201 Reduces C difficile Recurrence ]]&gt;</title><link>https://www.contagionlive.com/view/lmn-201-reduces-c-difficile-recurrence</link><guid isPermaLink="true">https://www.contagionlive.com/view/lmn-201-reduces-c-difficile-recurrence</guid><description>&lt;![CDATA[In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.]]&gt;</description><pubDate>Wed, 21 Oct 2026 11:12:54 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Maternal Vaccination Shown to Protect Against K Pneumoniae Neonatal Sepsis]]&gt;</title><link>https://www.contagionlive.com/view/maternal-vaccination-shown-to-protect-against-k-pneumoniae-neonatal-sepsis</link><guid isPermaLink="true">https://www.contagionlive.com/view/maternal-vaccination-shown-to-protect-against-k-pneumoniae-neonatal-sepsis</guid><description>&lt;![CDATA[The first animal model of neonatal sepsis to evaluate protection by maternal vaccination evidences transfer of immunity against virulent, often antibiotic-resistant Klebseilla pneumoniae.]]&gt;</description><pubDate>Tue, 20 Oct 2026 11:27:12 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[CHMP Backs Extended Use of AstraZeneca H5N1 Pandemic Flu Vaccine]]&gt;</title><link>https://www.contagionlive.com/view/chmp-backs-extended-use-of-astrazeneca-h5n1-pandemic-flu-vaccine</link><guid isPermaLink="true">https://www.contagionlive.com/view/chmp-backs-extended-use-of-astrazeneca-h5n1-pandemic-flu-vaccine</guid><description>&lt;![CDATA[The CHMP adopted a positive opinion on an extension of indication for AstraZeneca&apos;s H5N1 pandemic influenza vaccine at its October meeting.]]&gt;</description><pubDate>Mon, 19 Oct 2026 20:31:42 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Raw Cheddar Cheese Recall Flags Non-O157 E coli ]]&gt;</title><link>https://www.contagionlive.com/view/raw-cheddar-cheese-recall-flags-non-o157-e-coli-in-7-states</link><guid isPermaLink="true">https://www.contagionlive.com/view/raw-cheddar-cheese-recall-flags-non-o157-e-coli-in-7-states</guid><description>&lt;![CDATA[The company, Family Farmstead Dairy, issued a raw cheddar recall over potential contamination with Shiga toxin-producing Escherichia coli (STEC) is happening across 7 states.]]&gt;</description><pubDate>Mon, 19 Oct 2026 13:05:21 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[HHS Updates Guidelines for Antiretroviral Treatment of HIV]]&gt;</title><link>https://www.contagionlive.com/view/hhs-updates-guidelines-for-antiretroviral-treatment-of-hiv</link><guid isPermaLink="true">https://www.contagionlive.com/view/hhs-updates-guidelines-for-antiretroviral-treatment-of-hiv</guid><description>&lt;![CDATA[The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.]]&gt;</description><pubDate>Sun, 18 Oct 2026 12:32:23 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak]]&gt;</title><link>https://www.contagionlive.com/view/faq-ebola-prevention-treatment-and-the-chances-of-a-us-outbreak</link><guid isPermaLink="true">https://www.contagionlive.com/view/faq-ebola-prevention-treatment-and-the-chances-of-a-us-outbreak</guid><description>&lt;![CDATA[As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.]]&gt;</description><pubDate>Sat, 17 Oct 2026 13:41:10 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Ebola Outbreak in DRC Tops 9235 Confirmed Cases, CDC Reports]]&gt;</title><link>https://www.contagionlive.com/view/ebola-outbreak-in-drc-tops-9235-confirmed-cases-cdc-reports</link><guid isPermaLink="true">https://www.contagionlive.com/view/ebola-outbreak-in-drc-tops-9235-confirmed-cases-cdc-reports</guid><description>&lt;![CDATA[As of October 15, CDC reports 9235 confirmed cases and 4444 deaths in the Bundibugyo virus Ebola outbreak in the DRC, now the second-largest on record.]]&gt;</description><pubDate>Sat, 17 Oct 2026 13:10:56 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Measles Update: October 16, 2026]]&gt;</title><link>https://www.contagionlive.com/view/measles-update-october-16-2026</link><guid isPermaLink="true">https://www.contagionlive.com/view/measles-update-october-16-2026</guid><description>&lt;![CDATA[The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state&apos;s massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal. ]]&gt;</description><pubDate>Fri, 16 Oct 2026 16:51:14 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Candida auris Evades Antifungals Without FKS1 Mutations]]&gt;</title><link>https://www.contagionlive.com/view/candida-auris-evades-antifungals-without-fks1-mutations</link><guid isPermaLink="true">https://www.contagionlive.com/view/candida-auris-evades-antifungals-without-fks1-mutations</guid><description>&lt;![CDATA[Serial bloodstream isolates from two critically ill London patients showed heteroresistance, CRZ1 escape mutations, and drug-induced polyploidy despite wild-type FKS1 and susceptible MICs.]]&gt;</description><pubDate>Fri, 16 Oct 2026 11:57:37 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item></channel></rss>